Eledon Pharmaceuticals, Inc. Income Statement
ELDN|3 years of annual SEC 10-K data (FY2014-FY2016)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Eledon Pharmaceuticals, Inc. reported $0 in revenue and $23M in net loss for FY2016.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2016 | FY2015 | FY2014 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| SG&A Expense | $8.9M | $3.5M | $2.3M |
| R&D Expense | $14.6M | $12.2M | $7.4M |
| Operating Income | -$23.5M | -$15.7M | -$9.6M |
| Income Tax | $0 | $0 | $0 |
| Net Income | -$23.3M | -$15.7M | -$9.6M |
| EPS (Diluted) | -$3.60 | -$38.02 | -$31.09 |
| Shares Outstanding | 22.6M | 22.4M | 493.3K |